Aprea - Rasio nilai perusahaan marang dodolan APRE

Simbol resmi perusahaan Aprea Therapeutics Inc. (APRE)

Aprea Therapeutics focuses on developing targeted therapies to combat solid tumors by advancing its R&D cycle. The business's financial foundation relies on grants and successful clinical trials. Patent protection minimizes dumping, although risks persist due to competition from Big Pharma. The current level of 0.00 indicates the parameter's status, while the EV/Sales multiple on the GURU.Markets chart demonstrates the company's adaptation to borrowing costs.

Aprea Therapeutics, Inc. (APRE): Nilai perusahaan marang pendapatan saka 23.11.2025 nganti 20.11.2026

Aprea Therapeutics, Inc. - rincian analitis lan metrik utama (APRE)

- rega lan prakiraan konsensus rega:
Pambiji fundamental perusahaan:APRE, Aprea
Produk sing diprodhuksi aprea.com

This indicator measures the total business value relative to generated revenue, excluding the impact of debt load to identify capitalization overheating. By analyzing the current enterprise value-to-revenue ratio, an investor can assess the risk of a price correction amid the diversification of Aprea Therapeutics (APRE) into solid tumors and hematology segments, which potentially justifies a high market premium for the development of p53 protein therapy.

Analisis pesaing

Multiplikator nilai perusahaan marang pendapatan Incyte Corporation|HCM (HUTCHMED Corp) - Nilai perusahaan marang pendapatan|Rasio nilai perusahaan marang dodolan Nuvation Pharma NUVB|Nilai perusahaan marang pendapatan DAWN|Multiplikator nilai perusahaan marang pendapatan Monopar Therapeutics MNPR|Nilai perusahaan marang pendapatan INBX (Inhibrx Biosciences)|IMAB (I-Mab Inc.) - Nilai bisnis marang pendapatan|Fennec Pharmaceuticals - Nilai perusahaan marang pendapatan|Koefisien nilai perusahaan marang pendapatan HRTX (Heron Therapeutics Inc)|Nuvectis - Multiplikator EV/Sales|Nilai bisnis marang pendapatan CHRS (Coherus BioSciences Inc.)|CRBP: Multiplikator EV/Sales|Multiplikator nilai perusahaan marang pendapatan Cardiff Oncology Corp (CRDF)|Rasio nilai perusahaan marang pendapatan BeyondSpring|BCAB: Nilai bisnis marang pendapatan|Multiplikator EV/Sales LIXT|Multiplikator EV/Sales Citius Pharmaceuticals Inc. (CTXR)|Rasio nilai perusahaan marang pendapatan Cellectar CLRB|BLRX (BioLineRx) - Nilai perusahaan marang volume dodolan|CANF: Nilai perusahaan marang pendapatan|Multiplikator nilai perusahaan marang pendapatan Kazia Therapeutics Limited|Silexion Therapeutics Corp (SLXN) - Rasio nilai perusahaan marang pendapatan|Rasio nilai perusahaan marang pendapatan NCNA|CMRX (Chimerix, Inc.) - Multiplikator EV/Sales|Multiplikator nilai perusahaan marang pendapatan Cyclacel Pharmaceuticals CYCC|G1 Therapeutics Inc. (GTHX) - Nilai bisnis marang pendapatan|KRON - Multiplikator nilai perusahaan marang pendapatan|Kintara Therapeutics, Inc. - Nilai perusahaan marang pendapatan|Koefisien nilai perusahaan marang pendapatan ONCT (Oncternal)|Portage Biotech Corp - Multiplikator EV/Sales